ROS1 and lung carcinoma: However, it will not be pragmatically feasible to perform phase Ib/II clinical trials of discrete combination regimens for each individual therapy-resistant, rare molecular subset of lung cancer (e.g., ROS1-, RET-, and NTRK1-3-rearranged NSCLC) and for each distinct genomic mechanism of resistance.